Abstract
X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy. The severe Mediterranean variant (G6PD Med) is common across Europe and Asia, and is thought to confer protection against malaria but its effect is unclear. We fit a Bayesian statistical model to observed G6PD Med allele frequencies in 999 Pashtun patients with acute Plasmodium vivax malaria and 1408 population controls. G6PD Med was associated with a reduction in the incidence of symptomatic P. vivax malaria of 76% (95% CI 58-88) in hemizygous males and homozygous females combined, and of 55% (95% CI 38-68) in heterozygous females. Thus, in absence of very large population stratification (i.e. confounding) the G6PD Med genotype confers a very large and gene dose proportional protective effect against acute vivax malaria. The proportion of patients with vivax malaria at risk of haemolysis following 8-aminoquinoline radical cure is substantially overestimated by epidemiological studies in healthy subjects.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01178021
Funding Statement
Wellcome Trust: Major Overseas Programme-Thailand Unit Core Grant: 106698/B/14/Z
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical studies were approved by the Institutional Review Board of the Afghan Public Health Institute, Ministry of Public Health, Afghanistan, the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand, and the Oxford Tropical Research Ethics Committee, Oxford University, UK. The clinical trial was registered with the clinical trials website http://www.clinicaltrials.gov/ct under the identifier NCT01178021.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.